Logo image of OGI

ORGANIGRAM GLOBAL INC (OGI) Stock Fundamental Analysis

NASDAQ:OGI - Nasdaq - CA68620P7056 - Common Stock - Currency: USD

1.08  +0.02 (+1.89%)

After market: 1.0898 +0.01 (+0.91%)

Fundamental Rating

2

Taking everything into account, OGI scores 2 out of 10 in our fundamental rating. OGI was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of OGI have multiple concerns. OGI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OGI had negative earnings in the past year.
In the past year OGI has reported a negative cash flow from operations.
OGI had negative earnings in each of the past 5 years.
OGI had negative operating cash flow in 4 of the past 5 years.
OGI Yearly Net Income VS EBIT VS OCF VS FCFOGI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a decent Return On Assets value of -10.99%, OGI is doing good in the industry, outperforming 69.70% of the companies in the same industry.
OGI has a Return On Equity of -16.27%. This is in the better half of the industry: OGI outperforms 74.75% of its industry peers.
Industry RankSector Rank
ROA -10.99%
ROE -16.27%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
OGI Yearly ROA, ROE, ROICOGI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OGI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGI Yearly Profit, Operating, Gross MarginsOGI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OGI has more shares outstanding
Compared to 5 years ago, OGI has more shares outstanding
The debt/assets ratio for OGI is higher compared to a year ago.
OGI Yearly Shares OutstandingOGI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OGI Yearly Total Debt VS Total AssetsOGI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

OGI has an Altman-Z score of -0.95. This is a bad value and indicates that OGI is not financially healthy and even has some risk of bankruptcy.
OGI has a Altman-Z score (-0.95) which is in line with its industry peers.
A Debt/Equity ratio of 0.13 indicates that OGI is not too dependend on debt financing.
OGI has a Debt to Equity ratio of 0.13. This is comparable to the rest of the industry: OGI outperforms 49.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -0.95
ROIC/WACCN/A
WACC8.25%
OGI Yearly LT Debt VS Equity VS FCFOGI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

OGI has a Current Ratio of 3.36. This indicates that OGI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.36, OGI is in line with its industry, outperforming 57.58% of the companies in the same industry.
A Quick Ratio of 1.85 indicates that OGI should not have too much problems paying its short term obligations.
OGI has a Quick ratio (1.85) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 1.85
OGI Yearly Current Assets VS Current LiabilitesOGI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

OGI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.68%, which is quite impressive.
Looking at the last year, OGI shows a small growth in Revenue. The Revenue has grown by 7.33% in the last year.
Measured over the past years, OGI shows a quite strong growth in Revenue. The Revenue has been growing by 14.73% on average per year.
EPS 1Y (TTM)83.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.07%
Revenue 1Y (TTM)7.33%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%17.21%

3.2 Future

OGI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.43% yearly.
The Revenue is expected to grow by 17.26% on average over the next years. This is quite good.
EPS Next Y49.21%
EPS Next 2Y38.52%
EPS Next 3Y29.86%
EPS Next 5Y20.43%
Revenue Next Year48.03%
Revenue Next 2Y31.13%
Revenue Next 3Y26.16%
Revenue Next 5Y17.26%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
OGI Yearly Revenue VS EstimatesOGI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
OGI Yearly EPS VS EstimatesOGI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OGI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OGI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGI Price Earnings VS Forward Price EarningsOGI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGI Per share dataOGI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as OGI's earnings are expected to grow with 29.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y29.86%

More info and screens

0

5. Dividend

5.1 Amount

OGI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANIGRAM GLOBAL INC

NASDAQ:OGI (4/23/2025, 8:27:35 PM)

After market: 1.0898 +0.01 (+0.91%)

1.08

+0.02 (+1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners6.49%
Inst Owner Change0.64%
Ins Owners2.59%
Ins Owner ChangeN/A
Market Cap144.48M
Analysts77.78
Price Target1.98 (83.33%)
Short Float %6.53%
Short Ratio5.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-263.86%
Min EPS beat(2)-400%
Max EPS beat(2)-127.72%
EPS beat(4)1
Avg EPS beat(4)-141.69%
Min EPS beat(4)-400%
Max EPS beat(4)136.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.63%
Min Revenue beat(2)-12.23%
Max Revenue beat(2)2.96%
Revenue beat(4)2
Avg Revenue beat(4)-1.92%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)3.61%
Revenue beat(8)3
Avg Revenue beat(8)-3.83%
Revenue beat(12)5
Avg Revenue beat(12)-1.19%
Revenue beat(16)8
Avg Revenue beat(16)-0.53%
PT rev (1m)-0.23%
PT rev (3m)-15.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-125.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.2
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.9
BVpS1.75
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.99%
ROE -16.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.13%
Cap/Sales 3.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 1.85
Altman-Z -0.95
F-Score2
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)118.74%
Cap/Depr(5y)166.77%
Cap/Sales(3y)18.54%
Cap/Sales(5y)32.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.07%
EPS Next Y49.21%
EPS Next 2Y38.52%
EPS Next 3Y29.86%
EPS Next 5Y20.43%
Revenue 1Y (TTM)7.33%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%17.21%
Revenue Next Year48.03%
Revenue Next 2Y31.13%
Revenue Next 3Y26.16%
Revenue Next 5Y17.26%
EBIT growth 1Y6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.48%
EBIT Next 3Y48.57%
EBIT Next 5Y31.35%
FCF growth 1Y81.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.83%
OCF growth 3YN/A
OCF growth 5YN/A